-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $697

Benzinga·10/22/2026 16:22:30
Listen to the news
RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $708 to $697.